Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis

Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis

A pharmacovigilance study published in Cancers in October 2026 identified higher-than-expected reporting of pneumonia and influenza with teclistamab plus daratumumab in patients with relapsed or refractory multiple myeloma. The findings raise concerns about infectious complications when B-cell maturation antigen (BCMA)-directed T-cell engagement is combined with CD38-targeted immunotherapy.

Carmel Awadallah and colleagues analyzed more than 4.6 million reports in the FDA Adverse Event Reporting System (FAERS). Pneumonia was the most clinically relevant signal, although its statistical significance varied across analyses adjusting for treatment-population differences. Cytokine release syndrome, neurotoxicity, and individual cytopenias were reported less often than expected, which the investigators attributed mainly to reporting patterns and patient-group differences.

Background: Infectious Toxicity With Teclistamab and Daratumumab

Teclistamab is a BCMA × CD3 bispecific antibody that redirects T cells against malignant plasma cells. Daratumumab is an anti-CD38 monoclonal antibody that depletes malignant plasma cells and several immune-cell populations, including natural killer cells. BCMA-directed treatment adds hypogammaglobulinemia, impaired humoral immunity, and T-cell dysfunction, so the combination affects several components of immune defense.

The phase III MajesTEC-3 trial supported FDA approval of the combination in March 2026. The 36-month progression-free survival rate was 83.4% vs 29.7% with daratumumab-based standard-of-care regimens (hazard ratio, 0.17), and 3-year overall survival was 83.3% vs 65.0%.

Infections occurred in 96.5% of combination-treated patients, with grade 3 or higher infections in 54.1%. These rates led to intensified antimicrobial prophylaxis and immunoglobulin replacement. They did not show whether the combination produces more infectious toxicity than the individual agents would predict.

Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis

Study Design: FDA Adverse Event Reporting System Analysis

The investigators analyzed FAERS reports submitted between the fourth quarter of 2022 and the fourth quarter of 2025, from teclistamab’s initial commercial availability to the last complete quarter before approval of the combination. After deduplication, the database held 4,632,365 reports: 353 listing both drugs, 2,774 listing teclistamab without daratumumab, and 19,230 listing daratumumab without teclistamab. All combination reports preceded regulatory approval, so they may have come from clinical trials, expanded-access programs, or off-label use.

Reporting odds ratios (RORs) tested whether adverse events appeared disproportionately with each treatment. A multiplicative interaction ratio then tested whether events were reported with the combination more often (ratio above 1) or less often (ratio below 1) than the individual agents predicted. Sensitivity analyses addressed reporting period, sparse event counts, drug attribution, co-administered treatments, and myeloma population differences.

Pneumonia and Influenza: Principal Infectious Safety Signals

Infections were the most frequently reported category, appearing in 55.8% of combination reports vs 29.9% of teclistamab-only and 22.9% of daratumumab-only reports. Among individual infections:

  • Pneumonia: the most frequently reported infection, in 57 combination reports (approximately 16%), with higher reporting than expected (interaction ratio, 1.50).
  • Influenza: a positive interaction signal (interaction ratio, 2.63), based on only nine combination reports.
  • Respiratory tract infection and fungal pneumonia: elevated interaction ratios, with confidence intervals crossing 1 under the primary model.
  • Sepsis and COVID-19 pneumonia: disproportionately reported with the individual treatments and the combination, but neither exceeded the multiplicative expectation.

The positive interaction signal was therefore concentrated in selected respiratory infections. The investigators considered combined humoral and cellular immune impairment a plausible explanation: teclistamab-associated antibody depletion and T-cell dysfunction, together with daratumumab-associated changes in immune-cell populations, could weaken responses to respiratory pathogens.

Sensitivity Analyses: How Robust Was the Pneumonia Signal?

The pneumonia interaction ratio stayed directionally consistent across sensitivity analyses, but its significance depended on the comparison population:

  • Restricted to myeloma reports: 3.59
  • Adjusted for age, sex, reporting characteristics, calendar year, and co-reported antimyeloma drug classes: 3.08
  • Daratumumab comparison restricted to regimens used in relapsed disease: 1.43, no longer significant
  • Reports listing additional immunomodulatory drugs or proteasome inhibitors excluded: 1.53, based on 137 combination reports

The treatment cohorts were not equivalent. Teclistamab monotherapy was used predominantly in heavily pretreated patients, whereas daratumumab monotherapy reports spanned several treatment lines, including newly diagnosed disease. Reporting sources also differed: almost 98% of combination reports were expedited manufacturer submissions, which may include events captured systematically in clinical trials.

Nausea and fatigue departed from expected reporting patterns despite having no plausible interaction mechanism, so the model was sensitive to reporting differences unrelated to pharmacology. The pneumonia association is a clinically relevant signal that needs prospective confirmation.

Cytokine Release Syndrome and Neurotoxicity: Lower Reporting Does Not Mean Lower Risk

Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were reported less often than expected with the combination (interaction ratio, 0.15 and 0.11, respectively). Both events are strongly associated with teclistamab monotherapy, and their high single-agent reporting odds raise the expectation against which the combination is compared. For CRS, an interaction ratio of 1 would have required more than half of combination reports to mention the event, against an observed proportion of approximately 16%.

Expected toxicities managed during clinical trials may receive less emphasis in safety reports than serious infections, whereas spontaneous postmarketing reports of teclistamab monotherapy may favor prominently labeled reactions such as CRS and neurotoxicity. When the background population was restricted to myeloma reports, CRS and ICANS no longer differed significantly from the expected pattern.

The study provides no evidence that daratumumab protects against CRS or neurotoxicity. Both remain established concerns requiring monitoring and management per prescribing information.

Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis

Hematologic Toxicity: Cytopenias and Bone Marrow Failure

Neutropenia, thrombocytopenia, and anemia were also reported less often than expected (interaction ratio, 0.14-0.16). The investigators attributed this to patient-population differences, reporting practices, and the large background reporting odds of cytopenias with the individual treatments.

Bone marrow failure showed the opposite pattern: 13 combination reports, with an interaction ratio of 13.9. The estimate rested on four teclistamab-only reports and could not be reproduced in the more recent reporting period. It may reflect terminology, since bone marrow failure can describe prolonged multilineage cytopenias. A true increase in hematopoietic suppression cannot be excluded.

Reported Death Outcomes and Treatment-Population Differences

A death outcome was recorded in 15.6% of combination reports, 22.5% of teclistamab-only reports, and 10.2% of daratumumab-only reports. These proportions are not treatment-related mortality rates: FAERS lacks exposure denominators and the clinical information needed to separate treatment, disease progression, and other causes.

MajesTEC-3 enrolled patients with one to three prior lines of therapy, whereas teclistamab monotherapy was historically used in more advanced, heavily pretreated disease. The proportions cannot be used to compare survival or safety between regimens.

Clinical Implications

In MajesTEC-3, severe infections concentrated in the first six months and improved after protocol amendments strengthened infection prevention. Earlier MajesTEC-2 and TRIMM-2 experience included infection-related deaths before intensified supportive care.

The approved regimen includes immunoglobulin monitoring and replacement to keep serum immunoglobulin G above 400 mg/dL; hypogammaglobulinemia occurred in approximately 84% of combination-treated patients in the registration trial. Established supportive care remains the foundation: immunoglobulin replacement, Pneumocystis jirovecii and antiviral prophylaxis, and vaccination.

New respiratory symptoms or fever call for same-day assessment with pathogen testing and chest imaging, and active infections may require treatment interruption according to severity. Routine antibacterial or antifungal prophylaxis is not needed for every patient. The approved indication (at least one prior line including a proteasome inhibitor and an immunomodulatory agent) may bring in more heavily pretreated patients than the registration trial enrolled.

Limitations

FAERS does not capture exposure duration, disease burden, baseline immune status, or supportive care. Co-reporting does not confirm concurrent administration, and other antimyeloma agents may have contributed to the toxicities. The combination cohort was small, may include trial-derived reports, and was analyzed without adjustment for multiple comparisons, which raises the possibility of chance findings.

Source: Awadallah C, Irfan S, Abdallah AO, Abid MB. Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug–Interaction Analysis of the FDA Adverse Event Reporting System. Cancers. 2026;18(20):3388.

Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis

 

 

Mariam Khachatryan
Fact checked by Mariam Khachatryan MD, Medical Oncologist
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist